Active Substance: Fenofibrate.
Overview
Welcome to Dwaey, specifically on FENOGAL 200mg page.
This medicine contains an important and useful components, as it consists of
Fenofibrateis available in the market in concentration
Fenofibrate
Renal or hepatic impairment. Monitor LFTs and blood counts regularly. Increased risk of cholelithiasis, pancreatitis, skeletal muscle effects. Withdraw treatment if no adequate response after 2 mth of treatment at max recommended dose. Lactation: Unknown if excreted in breast milk; not recommended
Hyperlipidemia,Hypercholesterolaemia,Hypertriglyceridaemia
Hypersensitivity; severe hepatic and renal impairment. Unexplained persistent liver function abnormality and primary biliary cirrhosis; preexisting gall bladder disease. Pregnancy, lactation.
1-10% Abdominal pain (4.6%),Back pain (3.4%),Increased AST (3.4%),Headache (3.2%),Increased ALT (3%),Increased CPK (3%),Nausea (2.3%),Constipation (2.1%) Potentially Fatal: Hepatitis, cholecystitis.
3
Fenofibrate, a fibric acid derivative, lowers plasma triglyceride by activating lipoprotein lipase thus increasing catabolism of VLDL w/ consequent increase in HDL levels.
Decreased absorption w/ bile acid sequestrants (e.g. colestyramine). May increase risk of ciclosporin-induced nephrotoxicity. Increased risk of muscle toxicity w/ HMG-CoA reductase inhibitors (e.g. simvastatin). May increase risk of bleeding w/ oral anticoagulants.
Information not available